A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma

NCT07015242 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

65

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma

Interventions

DRUG: Rituximab
DRUG: Methotrexate
DRUG: Procarbazine
DRUG: Temozolomide
BIOLOGICAL: Liso-cel
DRUG: Fludarabine
DRUG: Cyclophosphamide
DRUG: Calcium folinate

Sponsor

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company